In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Irhythm Technologies (IRTC). The company’s shares closed last Wednesday at $84.25, close to its 52-week low of $77.43.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 7.6% and a 55.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $97.80, representing a 19.2% upside. In a report issued on April 12, J.P. Morgan also downgraded the stock to Hold with a $95.00 price target.
See today’s analyst top recommended stocks >>
Irhythm Technologies’ market cap is currently $2.46B and has a P/E ratio of -56.30. The company has a Price to Book ratio of 7.67.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IRTC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
